Background: The use of thrombolytics is frequently considered in patients with cerebral venous and dural sinus thrombosis (CVT) who deteriorate despite anticoagulant therapy. Purpose: To collect all the published information about the use of systemic thrombolysis in CVT in order to assess its efficacy and safety. Methods: We performed a PubMed search, checked all reference lists of studies found and used data from the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Outcome was classified at the last available follow-up by the modified Rankin Scale (mRS). The cases were stratified according to variables that might influence outcome. Results: A total of 16 reports (26 patients, 2 from the ISCVT and 24 from the systematic review of the literature) were included. No randomized clinical trial was found. Seven patients presented with isolated intracranial hypertension syndrome (26.9%), 17 with encephalopathy (65.4%) and 2 were comatose (7.7%). The superior sagittal sinus was the one most often affected (n = 21; 80.8%), and there was thrombosis of the deep cerebral venous system in 5 patients (19.2%). Urokinase was the thrombolytic agent most frequently administered (n = 19; 73.1%), whereas streptokinase and recombinant tissue plasminogen activator were used in 2 cases each (7.7%). Intracranial hemorrhages occurred in 3 cases (11.5%). Extracranial hemorrhages occurred in 5 cases (19.2%), and overall there were 3 cases of serious bleeding (11.5%), including 2 deaths (7.7%). Partial or complete recanalization was verified in most patients (n = 16; 61.5%). The survival rate was 92.3% (24/26 patients). At the last available follow-up, 22/25 patients regained independency (mRS scores 0-2; 88%), 2/25 died (mRS score 6; 8%) and 1/25 was severely dependent (mRS scores 3-5; 4%). Conclusions: In all, 88% of the CVT patients treated with systemic thrombolysis regained their independency, but 2 deaths associated with intracranial hemorrhage occurred. The mortality rate and disability at the last available follow-up were similar to those found in 2 previous systematic reviews concerning the use of thrombolytics in CVT. Due to the small sample size and lack of controls, the efficacy of systemic thrombolysis in acute CVT cannot be assessed from the published information. Concerning safety, a nonnegligible proportion of bleedings was reported.

Einhäupl K, Stam J, Bousser MG, de Bruijn SF, Ferro JM, Martinelli I, Masuhr F, European Federation of Neurological Societies: EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol 2010;17:1229-1235.
Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, deVeber G, Ferro JM, Tsai FY, American Heart Association Stroke Council and Council on Epidemiology and Prevention: Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:1158-1192.
Bousser MG: Cerebral venous thrombosis: nothing, heparin, or local thrombolysis? Stroke 1999;30:481-483.
Ciccone A, Canhão P, Falcão F, Ferro JM, Sterzi R: Thrombolysis for cerebral vein and dural sinus thrombosis. Cochrane Database Syst Rev 2004;1:CD003693.
Wasay M, Bakshi R, Bobustuc G, Kojan S, Sheikh Z, Dai A, Cheema Z: Cerebral venous thrombosis: analysis of a multicenter cohort from the United States. J Stroke Cerebrovasc Dis 2008;17:49-54.
Canhão P, Ferro JM, Stam J: Cerebral venous thrombosis; in Fisher M (ed): Handbook of Clinical Neurology. Amsterdam, Elsevier, 2009, vol 93, pp 809-822.
Benamer HT, Bone I: Cerebral venous thrombosis: anticoagulants or thrombolytic therapy? J Neurol Neurosurg Psychiatry 2000;69:427-430.
Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F, ISCVT Investigators: Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004;35:664-670.
Gala N, Agarwal N, Barrese J, Gandhi CD, Prestigiacomo CJ: Current endovascular treatment options of dural venous sinus thrombosis: a review of the literature. J Neurointerv Surg 2013;5:28-34.
de Bruijn SPTM, de Haan RJ, Stam J: Clinical features and prognostic factors for venous sinus thrombosis in a prospective series of 59 patients. J Neurol Neurosurg Psychiatry 2001;70:115-118.
Stam J: Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005;352:1791-1798.
Kamal AK: Thrombolytic therapy in cerebral venous sinus thrombosis. J Pak Med Assoc 2006;56:538-540.
Albumiya T, Echizenya K, Ihara T, Murai H, Satou M: A case of venous thrombosis associated with medullary venous malformation (in Japanese). No Shinkei Geka 1992;20:451-455.
Strzyzewska-Lubos L, Wajgt A, Wolwender K: Cerebral venous thrombosis: a young woman case study (in Polish). Neurol Neurochir Pol 2002;36:993-999.
Manthous CA, Chen H: Case report: treatment of superior sagittal sinus thrombosis with urokinase. Conn Med 1992;56:529-530.
Tsujikawa T, Urabe M, Bamba H, Andoh A, Sasaki M, Koyama S, Fujiyama Y, Bamba T: Haemorrhagic cerebral sinus thrombosis associated with ulcerative colitis: a case report of successful treatment by anticoagulant therapy. J Gastroenterol Hepatol 2000;15:688-692.
Huh PW, Cho KS, Yoo DS, Kim JK, Kim DS, Kang LK: Deep cerebral venous thrombosis. Acta Neurochir (Wien) 2002;144:103-105.
Tarani L, Iacobini M, de Stefano V, Smacchia MP, Tozzi MC, Raguso G, Bruni L: Recombinant plasminogen activator therapy for cerebral vein thrombosis in a child carrier of prothrombin gene mutation. J Pedriatr Hematol Oncol 2002;24:769-771.
Vines FS, Davis OD: Clinical-radiological correlation in cerebral venous occlusive disease. Radiology 1971;98:9-22.
Gettelfinger DM, Kokmen E: Superior sagittal sinus thrombosis. Arch Neurol 1977;34:2-6.
Misra V, Elliott DG, Gonzalez-Toledo E, Kelley RE: Demonstration of significant resolution of cerebral sino-venous thrombosis associated with intravenous recombinant tissue plasminogen activator. J Neuroimaging 2007;17:348-349.
di Rocco C, Iannelli A, Leone G, Moschini M, Valori VM: Heparin-urokinase treatment in aseptic dural sinus thrombosis. Arch Neurol 1981;38:431-435.
Nagatomo Y, Yanaka K, Kamezaki T, Kobayashi E, Matsumura A, Nose T: Recovery from primary deep cerebral venous sinus thrombosis with recanalisation. Neuroradiology 1995;37:645-648.
Ossemann M, Laloux P, Doyen C, Sonnet A, Dive A, Bulpa P, DeCoene B, Ide C: Systemic thrombolysis in cerebral venous thrombosis extended from the jugular vein. Cerebrovasc Dis 2000;10:247-248.
Funabiki Y, Fujii H, Fujitake J, Takasu K, Nishimura K, Hayakawa K, Tatsuoka Y: Four cases of cerebral venous sinus thrombosis. Eur Neurol 2002;48:228-230.
Nagai T, Tomizawa T, Tonooka N, Mita Y, Misumi S, Mori M: Diabetes mellitus with left transverse sinus thrombosis and right transverse sinus aplasia. Diabetes Res Clin Pract 2001;51:39-43.
Sakai T, Ogura Y, Kimura D, Narita J, Suto T, Fukuda I: Pulmonary embolism and cerebral venous thrombosis after thoracoscopic surgery for benign pulmonary disease. Gen Thorac Cardiovasc Surg 2008;56:570-574.
Canhão P, Falcão F, Ferro JM: Thrombolytics for cerebral sinus thrombosis: a systematic review. Cerebrovasc Dis 2003;15:159-166.
Dentali F, Squizzato A, Gianni M, de Lodovici ML, Venco A, Paciaroni M, Crowther M, Ageno W: Safety of thrombolysis in cerebral venous thrombosis: a systematic review of the literature. Thromb Haemost 2010;104:1055-1062.
Coutinho JM, Ferro JM, Zuurbier SM, Mink MS, Canhão P, Crassard I, Majoie CB, Reekers JA, et al: Thrombolysis or anticoagulation for cerebral venous thrombosis: rationale and design of the TO-ACT trial. Int J Stroke 2013;8:135-140.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.